Michael Joiner, Ph.D.
Director, Radiation Biology Program
Michael Joiner, Ph.D.
Address4201 St. Antoine
Detroit, MI 48201
Office Location:GROC Academic Area
I am the Director of Radiobiology in the Department of Radiation Oncology at WSU. I currently teach the Radiobiology course in the Graduate Program. I also teach at a number of international courses on radiation oncology, and host a week-long NIH sponsored course at WSU that focuses on the integration of radiobiology and radiation physics into clinical practice.
April 1988 - April 1997
Research Scientist, Tenured appointment, senior grade, CRC Gray Laboratory, Mount Vernon Hospital, Northwood, Middlesex, UK
April 1997 - February 2002
Research Scientist, Special appointment grade, CRC Gray Laboratory, Mount Vernon Hospital, Northwood, Middlesex, UK
February 2002 - present
Professor (tenured), Department of Radiation Oncology, Wayne State University School of Medicine, Detroit, MI USA
Hospital / Professional Appointments:
Head of Experimental Oncology, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, UK
Honorary Professor Associate, Brunel University, Uxbridge, Middlesex, UK
Honorary Professor, Department of Oncology, University College, London, UK
October 2001 - present
Head of Radiation Biology Program, Department of Radiation Oncology, Wayne State University, Detroit, MI, USA
Queens' College, University of Cambridge, Cambridge, UK
Institute of Cancer Research (Royal Postgraduate Medical School), University of London, London, UK
CRC Gray Laboratory, Mount Vernon Hospital, Northwood, Middlesex, UK
While my background is pure radiobiology, the overlap between models of radiation damage and the physics required to understand those models has generated a number of interesting research projects for me within the medical physics arena.
My current Research Interests include, but are not limited to:
- Molecular basis for clinical radiation resistance and diversity seen in the response to radiation therapy, including the study of cancer stem cells.
- Development of a complete system of treatment planning based on biologically effective dose to improve our ability to account for variability in biological factors such as radiosensitivity, hypoxia and cell proliferation from patient to patient.
- Investigation of soy isoflavones to enhance radiotherapy.
- Gene therapy and therapeutic use of stem cells for radioprotection of normal tissues.
- Development of high-LET radiotherapy.
- Nanoparticles to enhance the radiation effect on radioresistant tumors.
I do advise Master's student in their thesis work in the medical physics program. The research is usually biologically focused, including some lab work, with a heavy lean towards clinical applications of the outcomes and possible inclusion into the planning of hypofractionated treatment schedules.
- "B-DIM impairs radiation-induced survival pathways independently of androgen receptor expression and augments radiation efficacy in prostate cancer."
- "Bioeffect modeling and equieffective dose concepts in radiation oncology – Terminology, quantities and units."
- "Low energy fluorescent X-Ray dosimetry using ion chamber and film"
- "Relationships among micronuclei, nucleoplasmic bridges and nuclear buds within individual cells in the cytokinesis block micronucleus assay."
- "Estimating the lowest detectable dose of ionizing radiation by the cytokinesis-block micronucleus assay."
- "Differential effect of soy isoflavones in enhancing high dose radiotherapy and protecting lung tissue in a pre-clinical model of lung carcinoma."
- "Soy isoflavones protect normal tissue from radiation-induced injury."
- "Limitations of the bowel bag contouring technique in the definitive treatment of cervical cancer."